FMT

In the first clinical trial of its kind, faecal microbiota transplants were shown to improve immunotherapy response in advanced melanoma.

Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease

[Involvement of microbiota in IBD and bacteriotherapy]

gov: NCT04236843).

There is growing evidence that supports a role of gut dysbiosis in the pathogenesis of psoriasis (Pso). Thus, probiotic supplementation and fecal microbiota transplantation may serve as promising preventive and therapeutic strategies for patients with Pso. One of the basic mechanisms through which t …

This study provides real-world evidence and insights into the dysbiosis of the microbiota in patients exposed to conditioning regimen during HSCT. Independent of clinical and immunological factors, we demonstrated significant associations between relative bacteria abundances with the increasing seve …

In a world-first clinical trial published in the journal Nature Medicine, a multi-center study from Lawson Health Research Institute, the Centre hospitalier de l'Université de Montréal and the Jewish General Hospital (JGH) has found fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma.

The Phase I trial by Lawson Health Research Institute, the Centre hospitalier de l’Université de Montréal (CHUM), and the Jewish General Hospital (JGH) in Montreal is said to be a world-first.

Researchers have found that fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma.

The gut microbiota, the community of gut microorganisms that inhabit the gastrointestinal tract, plays a crucial role in modulating host immunity, met…

A groundbreaking clinical trial, published in the journal Nature Medicine, has demonstrated the safety and potential of fecal microbiota transplants (FMT)

Researchers have found that fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma.

Nature Medicine - In patients with advanced melanoma, fecal microbiota transplantation from healthy donors combined with the anti-PD-1 inhibitors nivolumab or pembrolizumab was well tolerated with...

La colitis fulminante por Clostridium difficile se caracteriza por el desarrollo de una inflamación aguda severa del colon, asociada a toxicidad sistémica, y es la forma más grave de colitis aguda con una mortalidad de hasta el 80%. Presentamos el caso de un varón de 45 años que acude al servicio de …

Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.

Joseph Reilly, BS, PharmD, BCGP, reviews the positive economic impact of use of live-jslm for treatment of CDI in a hospital setting.

FMT is a promising intervention for immunocompetent patients with recurrent C difficile infection. However, the safety of FMT remains inconclusive due to limited data on serious adverse events and mortality.

Nature Reviews Bioengineering - The role of the gut microbiome in human health and disease is being increasingly recognized. This Review discusses microbiome engineering strategies to treat the...

The use of faecal microbiota transplantation (FMT) for ulcerative colitis remains promising but is certainly not yet ready for prime time, according to an expert consensus. The first international consensus on FMT in the setting of IBD, published in Gut [link here], said there was even less evidence for FMT as a treatment for Crohn’s […]

Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

A hospital reviewed both treatments in a real-world clinical setting to determine the effectiveness in preventing early and late recurrences.

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in a serious public health burden worldwide. In addition to respiratory, heart, and gastrointestinal symptoms, patients infected with SARS-CoV-2 experience a …

Fecal microbiota transplantation (FMT) is used routinely to treat recurrent Clostridioides difficile infection (rCDI) and investigated as a treatment for numerous conditions associated with gut microbiota alterations. Metagenomic analyses have indicated that recipient colonization by donor ba …

Men demonstrate higher incidence and mortality rates of colorectal cancer (CRC) than women. This study aims to explain the potential causes of such sexual dimorphism in CRC from the perspective of sex-biased gut microbiota and metabolites. The results show that sexual dimorphism in colorectal tumori …

With the advent of next-generation sequencers and subsequent large national projects by the U.S. and Europe, scientific information and knowledge have been dramatically accumulated on the microbiome and data associated with various diseases. Ever since the surprising highly successful efficacy of re …

Practical use of fecal microbiota spores, live-brpk (formerly SER-109): an oral therapeutic for the prevention of recurrent Clostridioides difficile infection

Abstract. Almost every aspect of cancer can be influenced by microbiota including tumor onset, progression, and response to therapy. The increasing evidence of the role of microbiota in human health and disease has reinvigorated the interest in designing microbial products that can affect cancer outcomes. Researchers have made numerous attempts to develop safe, engineered biotherapeutic products for cancer treatment using synthetic biology tools. Despite the progress, only Bacillus Calmette-Guérin is approved for human use. Here, we highlight the recent advances and current challenges in using live bacteria as cancer therapeutics.